Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 14.4% in October

Entera Bio Ltd. (NASDAQ:ENTX) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totalling 40,400 shares, a decline of 14.4% from the September 30th total of 47,200 shares. Based on an average daily volume of 37,300 shares, the days-to-cover ratio is currently 1.1 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Entera Bio in a report on Monday, October 7th.

Hedge Funds Weigh In On Entera Bio

A hedge fund recently bought a new stake in Entera Bio stock. Virtu Financial LLC bought a new position in shares of Entera Bio Ltd. (NASDAQ:ENTX) in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 22,040 shares of the company’s stock, valued at approximately $37,000. Institutional investors and hedge funds own 14.11% of the company’s stock.

Entera Bio Trading Down 2.7 %

ENTX traded down $0.05 during midday trading on Thursday, hitting $1.81. 10,630 shares of the company were exchanged, compared to its average volume of 119,944. The company’s 50 day simple moving average is $1.86 and its 200 day simple moving average is $1.95. The firm has a market capitalization of $64.77 million, a price-to-earnings ratio of -6.56 and a beta of 1.57. Entera Bio has a 1-year low of $0.52 and a 1-year high of $3.35.

Entera Bio (NASDAQ:ENTX) last posted its earnings results on Friday, August 9th. The company reported ($0.06) EPS for the quarter, hitting the consensus estimate of ($0.06). The company had revenue of $0.06 million for the quarter. On average, equities analysts anticipate that Entera Bio will post -0.23 EPS for the current year.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.